BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) will likely be announcing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of $0.05 per share and revenue of $162.9070 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 3, 2025 at 8:30 AM ET.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analysts’ expectations of $149.59 million. The firm’s revenue was up 49.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.06) EPS. On average, analysts expect BioCryst Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $7.20 on Monday. The company has a market cap of $1.51 billion, a PE ratio of -40.00 and a beta of 1.05. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.31. The firm has a 50 day simple moving average of $7.70 and a 200 day simple moving average of $8.67.

Insider Activity at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director owned 65,352 shares in the company, valued at $556,145.52. This represents a 51.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BCRX. Qube Research & Technologies Ltd increased its stake in shares of BioCryst Pharmaceuticals by 152.3% during the 2nd quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company’s stock worth $21,266,000 after purchasing an additional 1,432,824 shares during the last quarter. Bank of America Corp DE increased its stake in shares of BioCryst Pharmaceuticals by 97.9% during the 2nd quarter. Bank of America Corp DE now owns 2,841,155 shares of the biotechnology company’s stock worth $25,457,000 after purchasing an additional 1,405,498 shares during the last quarter. BNP Paribas Financial Markets grew its stake in BioCryst Pharmaceuticals by 1,059.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,456,857 shares of the biotechnology company’s stock valued at $13,053,000 after buying an additional 1,331,230 shares during the last quarter. State Street Corp grew its stake in BioCryst Pharmaceuticals by 8.9% in the 2nd quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock valued at $76,208,000 after buying an additional 691,988 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in BioCryst Pharmaceuticals by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after buying an additional 640,704 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BCRX shares. Royal Bank Of Canada reiterated an “outperform” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. TD Cowen started coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research note on Friday. Finally, Cantor Fitzgerald upped their price objective on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.18.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.